Business
Grant of further European patent
Grant of further European patent.
About this update from Theracryf Plc
[{"type":"text","content":"\n \nRNS Number : 1496I Evgen Pharma PLC 07 August 2019 \n\n7 August 2019 \nEvgen Pharma plc\n (\"Evgen Pharma\" or \"the Company\")\n \nGrant of further European patent covering composition of SFX-01\n \nEvgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces the grant of further intellectual property rights in Europe pertaining to the novel composition, SFX-01.\n \nThe newly granted patent leads with a product claim covering \"a composition comprising a complex of sulforaphane and alpha-cyclodextrin\". Composition-of-matter patents have already been granted in the USA and other territories. Furthermore, patents in Europe, the US and other territories relating to the method of production have also been granted.\n \nDetails of the European patent announced today, numbered EP3354267 and entitled Stablilized Sulforaphane, can be viewed at this link: \nhttps://register.epo.org/application?number=EP18162130&lng=en&tab=doclist\n \nExclusive worldwide rights to the patent are held by Evgen Pharma under the terms of a licence agreement with PharmAgra Labs Inc., the US laboratory that invented SFX-01.\n \nSteve Franklin, CEO of Evgen Pharma, said: ''We are delighted by the grant of this important patent in Europe. This patent has broad claims relating to the composition of the novel drug substance, SFX-01, and as such represents a material development for the Company. It further expands the strength and depth of our intellectual property position across all the key territories with regard to the composition of the product and method of manufacture. The overall intellectual property position around SFX-01 and novel analogues has matured into an impressive patent estate, asserting our exclusive position around this new class of pharmaceutical.\" \n \nEnquiries:\n \n\n\n\nEvgen Pharma plc www.evgen.com\n\n\nvia Walbrook\n\n\n\n\nDr Stephen Franklin, CEO\n\n\n\n\n\n\n\nRichard Moulson, CFO\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nfinnCap www.finncap.com\n\n\n+44 (0) 20 7220 0500 \n\n\n\n\nGeoff Nash / Teddy Whiley (Corporate Finance)\n\n\n\n\n\n\n\nAlice Lane, Manasa Patil (ECM)\n\n\n\n\n\n\n\n\n\n\n\n...